Mary Ellen Vajravelu1,2,3, Talia A Hitt1,3, Sandra Amaral3,4, Lorraine E Levitt Katz1,2, Joyce M Lee5, Andrea Kelly1,2. 1. Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 2. University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA. 3. Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 4. Division of Nephrology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 5. Susan B Meister Child Health Evaluation and Research Center, Division of Pediatric Endocrinology, University of Michigan, Ann Arbor, Michigan, USA.
Abstract
BACKGROUND: Due to high rates of comorbidities and rapid progression, youth with Type 2 diabetes may benefit from early and aggressive treatment. However, until 2019, the only approved medications for this population were metformin and insulin. OBJECTIVE: To investigate patterns and predictors of treatment escalation within 5 years of metformin monotherapy initiation for youth with Type 2 diabetes in clinical practice. SUBJECTS: Commercially-insured patients with incident youth-onset (10-18 years) Type 2 diabetes initially treated with metformin only. METHODS: Retrospective cohort study using a patient-level medical claims database with data from 2000 to 2020. Frequency and order of treatment escalation to insulin and non-insulin antihyperglycemics were determined and categorized by age at diagnosis. Cox proportional hazards regression was used to evaluate potential predictors of treatment escalation, including age, sex, race/ethnicity, comorbidities, complications, and metformin adherence (medication possession ratio ≥ 0.8). RESULTS: The cohort included 829 (66% female; median age at diagnosis 15 years; 19% Hispanic, 17% Black) patients, with median 2.9 year follow-up after metformin initiation. One-quarter underwent treatment escalation (n = 207; 88 to insulin, 164 to non-insulin antihyperglycemic). Younger patients were more likely to have insulin prescribed prior to other antihyperglycemics. Age at diagnosis (HR 1.14, 95% CI 1.07-1.21), medication adherence (HR 4.10, 95% CI 2.96-5.67), Hispanic ethnicity (HR 1.83, 95% CI 1.28-2.61), and diabetes-related complications (HR 1.78, 95% CI 1.15-2.74) were positively associated with treatment escalation. CONCLUSIONS: In clinical practice, treatment escalation for pediatric Type 2 diabetes differs with age. Off-label use of non-insulin antihyperglycemics occurs, most commonly among older adolescents.
BACKGROUND: Due to high rates of comorbidities and rapid progression, youth with Type 2 diabetes may benefit from early and aggressive treatment. However, until 2019, the only approved medications for this population were metformin and insulin. OBJECTIVE: To investigate patterns and predictors of treatment escalation within 5 years of metformin monotherapy initiation for youth with Type 2 diabetes in clinical practice. SUBJECTS: Commercially-insured patients with incident youth-onset (10-18 years) Type 2 diabetes initially treated with metformin only. METHODS: Retrospective cohort study using a patient-level medical claims database with data from 2000 to 2020. Frequency and order of treatment escalation to insulin and non-insulin antihyperglycemics were determined and categorized by age at diagnosis. Cox proportional hazards regression was used to evaluate potential predictors of treatment escalation, including age, sex, race/ethnicity, comorbidities, complications, and metformin adherence (medication possession ratio ≥ 0.8). RESULTS: The cohort included 829 (66% female; median age at diagnosis 15 years; 19% Hispanic, 17% Black) patients, with median 2.9 year follow-up after metformin initiation. One-quarter underwent treatment escalation (n = 207; 88 to insulin, 164 to non-insulin antihyperglycemic). Younger patients were more likely to have insulin prescribed prior to other antihyperglycemics. Age at diagnosis (HR 1.14, 95% CI 1.07-1.21), medication adherence (HR 4.10, 95% CI 2.96-5.67), Hispanic ethnicity (HR 1.83, 95% CI 1.28-2.61), and diabetes-related complications (HR 1.78, 95% CI 1.15-2.74) were positively associated with treatment escalation. CONCLUSIONS: In clinical practice, treatment escalation for pediatric Type 2 diabetes differs with age. Off-label use of non-insulin antihyperglycemics occurs, most commonly among older adolescents.
Authors: Rebecca E Hasson; Tanja C Adam; Jaimie N Davis; Marc J Weigensberg; Emily E Ventura; Christianne J Lane; Christian K Roberts; Michael I Goran Journal: J Clin Endocrinol Metab Date: 2010-05-05 Impact factor: 5.958
Authors: Victor W Zhong; Jihad S Obeid; Jean B Craig; Emily R Pfaff; Joan Thomas; Lindsay M Jaacks; Daniel P Beavers; Timothy S Carey; Jean M Lawrence; Dana Dabelea; Richard F Hamman; Deborah A Bowlby; Catherine Pihoker; Sharon H Saydah; Elizabeth J Mayer-Davis Journal: J Am Med Inform Assoc Date: 2016-04-23 Impact factor: 4.497
Authors: Angela Badaru; Georgeanna J Klingensmith; Dana Dabelea; Elizabeth J Mayer-Davis; Lawrence Dolan; Jean M Lawrence; Santica Marcovina; Daniel Beavers; Beatriz L Rodriguez; Giuseppina Imperatore; Catherine Pihoker Journal: Diabetes Care Date: 2013-09-11 Impact factor: 19.112
Authors: William V Tamborlane; Morey W Haymond; David Dunger; Ravi Shankar; Rose Gubitosi-Klug; Kathleen Bethin; Janina Karres; Paolo Tomasi; Ingrid Libman; Paula H Hale; Ronald Portman; Georgeanna Klingensmith; Michael Reed; Jeffrey Blumer; George Giacoia Journal: Diabetes Care Date: 2016-03 Impact factor: 19.112
Authors: Phil Zeitler; Kathryn Hirst; Kenneth C Copeland; Laure El Ghormli; Lorraine Levitt Katz; Lynne L Levitsky; Barbara Linder; Paul McGuigan; Neil H White; Denise Wilfley Journal: Diabetes Care Date: 2015-11-04 Impact factor: 19.112